Clinical Management of Liver Cancers

Dear Colleagues,

Liver carcinoma, characterized as a significant and prevalent malignancy, is a leading contributor to the global mortality burden. Its insidious nature is marked by an initial absence of discernible symptoms, often resulting in a delayed diagnosis when the disease has progressed to an advanced stage. This cancer typically originates from sustained hepatic damage, which acts as a catalyst for the transformation of normal hepatic cells into oncogenic entities.

The pathogenesis of liver carcinoma is multifaceted, with several risk factors playing a crucial role. Prominent among these are lifestyle-related choices such as excessive tobacco use and alcohol consumption. Additionally, viral etiologies, particularly infections caused by hepatitis B and C viruses, significantly enhance the risk of developing this malignancy. These factors collectively contribute to the induction of mutations within the cellular DNA, leading to a cascade of genetic disruptions.

The mutations caused by these risk factors are not trivial; they fundamentally alter the genomic landscape of the cells. These genetic aberrations critically interfere with the cellular regulatory networks that are responsible for maintaining normal cell behavior. Specifically, they disrupt the processes of cellular proliferation, apoptosis (programmed cell death), and differentiation. This disruption creates an environment conducive to uncontrolled cell growth and division, a hallmark of cancerous transformations, thereby driving the progression of hepatic carcinogenesis.

This upcoming Special Issue is poised to offer a comprehensive exploration of liver carcinoma, bridging the gap between basic scientific research and clinical practice. It aims to provide insights and updates that are relevant to a wide spectrum of readers, ranging from researchers in basic sciences, to practicing medical professionals specializing in hepatic oncology. While this Special Issue will primarily concentrate on specific topics within the field, it is designed to transcend these initial boundaries, potentially encompassing a broader range of subjects related to liver cancer, its etiology, progression, and treatment modalities. This approach underscores this Special Issue’s commitment to providing a holistic and in-depth understanding of liver carcinoma, contributing significantly to the ongoing discourse in this critical area of medical research and patient care.

You may choose our Joint Special Issue in JCM.

Dr. Jayant Kumar
Dr. Isabella Reccia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocellular carcinoma
• cholangiocarcinoma
• mixed hepatocellular carcinoma&ndash
• cholangiocarcinoma
• combined hepatocellular carcinoma-cholangiocarcinoma
• liver cancers